Former executives with generic drug firms charged with anticompetitive scheme

In the first charges brought by the Justice Department’s antitrust division involving generic drugs, two ex-senior executives with generic pharmaceutical companies were charged with an anticompetitive scheme, the government said on Dec. 14. Felony charges unsealed in Pennsylvania federal court allege that Jeffrey Glazer, the former CEO of a generic